ARTICLE | Company News

UCB divests six products

July 30, 2010 11:50 PM UTC

UCB Group (Euronext:UCB) granted Actient Pharmaceuticals LLC (Deerfield, Ill.) rights to market six drugs in the U.S. UCB will receive an upfront payment and is eligible for royalties. Actient also has an option to purchase the products, which include erectile dysfunction drug Edex alprostadil and hypertension drug Levatol penbutolol. UCB said the products had 2009 gross sales of $53 million. Further terms were not disclosed. ...